Paul Kirsch
Internal Medicine · Bradford, PANPI 1598759128
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.0% of the total across 473 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 28 manufacturers, the largest accounting for just 18.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $2,056 and has fallen 96.6% since, to $70 in 2025. Among internal medicine clinicians in PA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 473 payments — averaging $15.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$1K
- AstraZeneca$1K
- Merck$595
- Pfizer$534
- Amgen$448
- Boehringer Ingelheim$427
- plus $3K from 22 others
What the payments were for
- Food & beverage$7,41799%
- Education$781%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 95 | $1,399 |
| AstraZeneca | 67 | $1,076 |
| Merck | 41 | $595 |
| Pfizer | 39 | $534 |
| Amgen | 31 | $448 |
| Boehringer Ingelheim | 32 | $427 |
| Novo Nordisk | 26 | $386 |
| Takeda Pharmaceuticals U.S.A., Inc. | 26 | $357 |
| AbbVie(2 entities) | 19 | $303 |
| Bayer | 12 | $299 |
| Sanofi-aventis U.S. LLC | 14 | $243 |
| Lilly USA, LLC | 10 | $225 |
| GSK | 14 | $221 |
| Novartis | 11 | $180 |
| Biohaven Pharmaceuticals, Inc. | 7 | $164 |
| Biohaven Pharmaceutical Holding Company Ltd. | 7 | $161 |
| Amarin Pharma, Inc. | 7 | $105 |
| Exact Sciences | 1 | $94 |
| Dexcom, Inc. | 1 | $70 |
| Grifols USA, LLC | 3 | $56 |
| Esperion Therapeutics, Inc. | 3 | $41 |
| Shire North American Group Inc | 1 | $21 |
| Sunovion Pharmaceuticals Inc. | 1 | $20 |
| Tactile Systems Technology Inc | 1 | $20 |
| Boston Scientific | 1 | $15 |
| Astellas Pharma US Inc | 1 | $12 |
| E.r. Squibb & Sons, L.L.C. | 1 | $12 |
| Teva Pharmaceuticals USA, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,496 in reported general payments places this provider in the 90th percentile of 5,705 internal medicine providers in Pennsylvania.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Nebivolol Hcl | 12 | $454 |
| Atorvastatin Calcium | 34 | $431 |
| Glimepiride | 22 | $314 |
| Losartan Potassium | 16 | $292 |
| Rosuvastatin Calcium | 14 | $258 |
| Levothyroxine Sodium | 21 | $161 |
| Pantoprazole Sodium | 11 | $137 |
| Glipizide | 12 | $122 |
| Amlodipine Besylate | 20 | $58 |
| Lisinopril | 16 | $58 |
| Hydrochlorothiazide | 14 | $40 |
| Lovastatin | 11 | $26 |
| Omeprazole | 12 | $22 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Bradford
- Jonathan EpsteinPhiladelphia$13.1M
- Pitamber DevgonPhiladelphia$7.5M
- Daniel RaderPhiladelphia$1.7M
- Mohammed KidwaiBala Cynwyd$894K
- Ronak BhimaniNorristown$623K
- David GoldmannPhiladelphia$525K
- Christopher StillDanville$442K
- Jeffrey FreidLower Gwynedd$425K
- Cheryl PegusSpring House$370K
- Eyob FeyssaPhiladelphia$328K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.